ArticleScientific reports2026
Assessment of lipid mediators in the urine of patients with Lyme disease, tick-borne encephalitis and human granulocytic anaplasmosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To assess the host response to mono- and co-infection of tick-borne encephalitis (TBE) virus with Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum bacteria, as well as the possibility of using the analysis of the level of endocannabinoids and eicosanoids in urine for effective diagnostics. Urine of patients with Lyme disease (LD) (in the form of erythema migrans (EM) or neuroborreliosis (NB)), TBE, diagnosed by ELISA-based detection of serum and CSF anti-TBEV IgM and IgG antibodies in all cases, human granulocytic anaplasmosis (HGA), co-infection of TBEV, LD, and healthy individuals (Control Group, CG) was analyzed. A GC/LC-MS/MS platform was used to identify changes in the phospholipid metabolite profile in urine. Lipid peroxidation product levels were estimated by measuring 4-hydroxy-2-nonenal (4-HNE by GC-MS/MS and F2-isoprostanes 8-isoPGF2α by LC-MS/MS). Endocannabinoids and eicosanoids levels were assessed using LC-MS/MS. Statistically significant differences in the concentration of 8-isoP (EM, NB, TBE vs. CG) were observed in patients' urine before treatment. However, the analysis of endocannabinoids showed significant differences in oleylethanolamide (OEA) concentration (TBE vs CG). The study of pro-inflammatory eicosanoid levels showed a difference for: prostaglandin E2 (PGE2) (TBE vs CG), leukotriene D4 LTD4 (EM vs HGA), and 5-hydroxyeicosatetraenoic acid (5-HETE) (EM vs NB), assessed before treatment. The levels of anti-inflammatory eicosanoids showed a difference for prostaglandin D2 (PGD2) (EM vs CG) and 15-hydroxyeicosatetraenoic acid (15-HETE) (TBE vs CG). However, the results in the level of phospholipid metabolites from patients after therapy did not show statistically significant differences compared to the value before treatment and between groups. Tick-borne diseases are accompanied by changes in lipid metabolism, both ROS- and enzyme-dependent, which can be identified even in urine. Urinary lipid mediators show potential as supportive markers but require validation in larger patient cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.